Drug intelligence / Profile preview

Niludipine

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Niludipine is a 1,4-dihydropyridine derivative and a calcium channel blocker. It functions by inhibiting the transport of calcium ions through voltage-sensitive calcium channels, including L-type Ca2+ channels, and also interacts with mitochondrial Ca2+ antagonist receptors. This mechanism leads to vasodilation, making it effective in the treatment of angina pectoris and exhibiting hypotensive effects. Additionally, Niludipine has been shown to potentiate the activity of certain antitumor agents, suggesting its potential as an adjunct in cancer chemotherapy by reversing drug resistance.

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on Niludipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niludipine.

Explore the full profile